GENOMONCOLOGY LLC

Company Overview

GenomOncology LLC, founded in 2012, is developing and marketing software for handling and analyzing NGS data for cancer applications. The company markets two platforms: GenomAnalytics for research applications and GO Clinical Workbench for clinical applications.

GenomAnalytics is a software program for analyzing large cancer datasets, whereas the GO Clinical Workbench analyzes tumor variants in clinical applications. Both platforms are designed to enable a single workflow from NGS data files through to the final report.

In August 2018, GenomOncology licensed important technology from the University of Nebraska Medical Center. The technology automates the coding and mining of molecular pathology test results to assist clinicians in determining the effectiveness of targeted cancer treatments.

In September 2018, GenomOncology formed an alliance with Fluidigm to create an integrated workflow for immune-oncology research. The workflow, called Immuno-Oncology Gene Expression Workflow, combined Fluidigm’s Advanta Immuno-Oncology Gene Expression Assay with GenomOncology’s data analysis software (GO Immuno-Oncology Workbench).

In October 2020, GenomOncology launched igniteIQ, a product designed to efficiently extract clinically relevant data from scanned or digital PDF reports (e.g., pathology or NGS reports) and convert that data to discrete data elements. The product is designed to streamline data validation and analysis to create actionable information.

Also in October 2020, GenomOncology released its latest version of Pathology Workbench Tool, which is optimized for large panel (such as Illumina’s TSO500) and higher sample throughputs.

Company's Business Segments

• Oncology Platform : This Oncology Platform includes end-to-end Clinical Informatics solutions for Cancer, empowering Research, Decision-making within Precision Oncology Workflows.